Evidence map›Paper›PMID 36003890›Full record

ArticleSAGE open medical case reports2022

Reactive infectious mucocutaneous eruption - repeat etanercept after intravenous immunoglobulin: A case report.

Rochelle Tonkin, Malika Ladha, Nicole Johnson, William F Astle, Ami Britton, Neil H Shear, Luis Murguía-Favela, Michele Ramien

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medical case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rochelle TonkinDivision of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.ORCID https://orcid.org/0000-0002-5532-0250
Malika LadhaDepartment of Dermatology, University of Toronto, Toronto, ON, Canada.
Nicole JohnsonSection of Rheumatology, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
William F AstlePediatric Ophthalmology, Vision Clinic, Alberta Children's Hospital, Department of Surgery, University of Calgary, Calgary, AB, Canada.
Ami BrittonWound Care/Surgery Clinic Nurse, Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada.
Neil H ShearDepartment of Dermatology, University of Toronto, Toronto, ON, Canada.
Luis Murguía-FavelaSection of Hematology and Immunology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada.
Michele RamienDivision of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.
University of Calgary · CASunnybrook Health Science Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reactive infectious mucocutaneous eruption is a recently distinguished mucosal-predominant blistering eruption triggered by respiratory infections. We describe a previously healthy 11-year-old Black female with rapidly progressive mucocutaneous blistering after prodromal respiratory infection symptoms. Reactive infectious mucocutaneous eruption was suspected and treated with systemic corticosteroids followed by etanercept. Twenty-four hours after etanercept, the diagnosis of multisystem inflammatory syndrome in children was raised and intravenous immunoglobulin was given. Rapidly worsening mucocutaneous disease ensued but was controlled by a second dose of etanercept. Our case highlights the following: (1) the novel observation of possible interaction/neutralization of etanercept by intravenous immunoglobulin, (2) the challenging differential diagnosis of multisystem inflammatory syndrome in children for reactive infectious mucocutaneous eruption patients in the Coronavirus disease 2019 (COVID-19) pandemic, and (3) the role of early treatment to prevent dyspigmentation.

Indexed as

Coronavirus disease 2019Etanerceptintravenous immunoglobulinmycoplasma-induced rash and mucositisreactive infectious mucocutaneous eruption

Identifiers

PMID36003890
PMCPMC9393491
OpenAlexW4292079462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.